Drug intelligence / Profile preview

evodenoson

Development stage: Phase 2
Lead developer: Adenosine Therapeutics
Modality: Small Molecules
Administration: Ophthalmic

Overview

Evodenoson is a small molecule drug that acts as a selective adenosine A2a receptor agonist. It was developed primarily for ophthalmic use, specifically targeting the reduction of intraocular pressure in conditions such as primary open-angle glaucoma and ocular hypertension. The mechanism of action involves activation of the adenosine A2a receptor (A2aR), which can lead to vasodilation and modulation of immune responses. Evodenoson reached Phase 2 clinical trials but development was discontinued for its main indications. The original developer is Allergan UC, with Santen Pharmaceutical Co., Ltd. also involved in later-stage development[8].

Other names: evodenosonATL313ATL-313ATL 313

Targets

ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on evodenoson.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on evodenoson.

Explore the full profile